Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8TC12

UPID:
RDH11_HUMAN

ALTERNATIVE NAMES:
Androgen-regulated short-chain dehydrogenase/reductase 1; HCV core-binding protein HCBP12; Prostate short-chain dehydrogenase/reductase 1; Retinal reductase 1; Short chain dehydrogenase/reductase family 7C member 1

ALTERNATIVE UPACC:
Q8TC12; A6NDK3; A8K062; B2RB26; B4DDW0; Q0QD40; Q6IAH5; Q9NRW0; Q9Y391

BACKGROUND:
The enzyme Retinol dehydrogenase 11, also known as RDH11, is integral to the retinoid metabolism pathway, impacting vision and cell differentiation. It is recognized under various aliases, including Prostate short-chain dehydrogenase/reductase 1, highlighting its diverse biological roles. RDH11's enzymatic activity favors NADP and is crucial for converting retinol to retinal, facilitating the visual cycle and retinoic acid synthesis.

THERAPEUTIC SIGNIFICANCE:
The link between RDH11 and the syndrome involving Retinal dystrophy, juvenile cataracts, and short stature underlines the enzyme's therapeutic potential. By elucidating RDH11's role in this syndrome, researchers can pave the way for innovative treatments for retinal dystrophies and other related visual impairments, offering new avenues for improving patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.